{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:14:51Z","timestamp":1760296491739,"version":"3.41.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1023\/a:1012217820507","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T12:42:15Z","timestamp":1040647335000},"page":"225-237","source":"Crossref","is-referenced-by-count":8,"title":["Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat"],"prefix":"10.1007","volume":"68","author":[{"given":"Claus","family":"Holst-Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross W.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Carmeliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Br\u00fcnner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"357942_CR1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/scbi.1996.0020","volume":"7","author":"WG Stetler-Stevenson","year":"1996","unstructured":"Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 7: 147-154, 1996","journal-title":"Semin Cancer Biol"},{"key":"357942_CR2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/oxfordjournals.annonc.a059091","volume":"6","author":"PD Brown","year":"1995","unstructured":"Brown PD, Giavazzi R: Matrix metalloproteinase inhibition-a review of anti-tumour activity. Ann Oncol 6: 967-974, 1995","journal-title":"Ann Oncol"},{"key":"357942_CR3","first-page":"4726","volume":"54","author":"X Wang","year":"1994","unstructured":"Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726-4728, 1994","journal-title":"Cancer Res"},{"key":"357942_CR4","first-page":"3629","volume":"55","author":"SA Watson","year":"1995","unstructured":"Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55: 3629-3633, 1995","journal-title":"Cancer Res"},{"key":"357942_CR5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jnci\/87.20.1546","volume":"87","author":"J Sledge-GW","year":"1995","unstructured":"Sledge-GW J, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550, 1995","journal-title":"J Natl Cancer Inst"},{"key":"357942_CR6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/87.4.293","volume":"87","author":"G Taraboletti","year":"1995","unstructured":"Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87: 293-298, 1995","journal-title":"J Natl Cancer Inst"},{"key":"357942_CR7","first-page":"1207","volume":"2","author":"JA Low","year":"1996","unstructured":"Low JA, Johnson MD, Bone EA, Dickson RB: The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Can Res 2: 1207-1214, 1996","journal-title":"Clin Can Res"},{"key":"357942_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1006115218786","volume":"52","author":"RW Stephens","year":"1998","unstructured":"Stephens RW, Br\u00fcnner N, J\u00e4nicke F, Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52: 99-111, 1998","journal-title":"Breast Cancer Res Treat"},{"key":"357942_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z","volume":"72","author":"PA Andreasen","year":"1997","unstructured":"Andreasen PA, Kj\u00f8ller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis-a review. Int J Cancer 72: 1-22, 1997","journal-title":"Int J Cancer"},{"key":"357942_CR10","first-page":"168","volume":"74","author":"BS Nielsen","year":"1996","unstructured":"Nielsen BS, Sehested M, Timshel S, Pyke C, Dan\u00f8 K: Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74: 168-177, 1996","journal-title":"Lab Invest"},{"key":"357942_CR11","first-page":"111","volume":"138","author":"J Gr\u00f8ndahl-Hansen","year":"1991","unstructured":"Gr\u00f8ndahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Dan\u00f8 K: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138: 111-117, 1991","journal-title":"Am J Pathol"},{"key":"357942_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ijc.2910570419","volume":"57","author":"J R\u00f8mer","year":"1994","unstructured":"R\u00f8mer J, Pyke C, Lund LR, Eriksen J, Kristensen P, R\u00f8nne E, H\u00f8yer-Hansen G, Dan\u00f8 K, Br\u00fcnner N: Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 57: 553-560, 1994","journal-title":"Int J Cancer"},{"key":"357942_CR13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJM197705052961801","volume":"296","author":"Z Werb","year":"1977","unstructured":"Werb Z, Mainardi CL, Vater CA, Harris ED, Jr: Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 296: 1017-1023, 1977","journal-title":"N Engl J Med"},{"key":"357942_CR14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/ng1297-439","volume":"17","author":"P Carmeliet","year":"1997","unstructured":"Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17: 439-444, 1997","journal-title":"Nat Genet"},{"key":"357942_CR15","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1083\/jcb.110.4.1361","volume":"110","author":"RM Lyons","year":"1990","unstructured":"Lyons RM, Gentry LE, Purchio AF, Moses HL: Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 110: 1361-1367, 1990","journal-title":"J Cell Biol"},{"key":"357942_CR16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1083\/jcb.110.3.767","volume":"110","author":"O Saksela","year":"1990","unstructured":"Saksela O, Rifkin DB: Release of basic fibroblast growth factor-heparan sulphate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 110: 767-775, 1990","journal-title":"J Cell Biol"},{"key":"357942_CR17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/bjc.1996.29","volume":"73","author":"F Leonessa","year":"1996","unstructured":"Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman J, Gottesman MM, Clarke R: MDA435\/LCC6 and MDA435\/LCC6MDR1: ascites models of human breast cancer. Br J Cancer 73: 154-161, 1996","journal-title":"Br J Cancer"},{"key":"357942_CR18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/368419a0","volume":"368","author":"P Carmeliet","year":"1994","unstructured":"Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424, 1994","journal-title":"Nature"},{"key":"357942_CR19","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1083\/jcb.115.6.1763","volume":"115","author":"P Kristensen","year":"1991","unstructured":"Kristensen P, Eriksen J, Blasi F, Dan\u00f8 K: Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 115: 1763-1771, 1991","journal-title":"J Cell Biol"},{"key":"357942_CR20","first-page":"297","volume":"12","author":"SM Camiolo","year":"1982","unstructured":"Camiolo SM, Siuta MR, Madeja JM: Improved medium for extraction of plasminogen activator from tissue. Prep Biochem 12: 297-305, 1982","journal-title":"Prep Biochem"},{"key":"357942_CR21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1055\/s-0038-1649931","volume":"74","author":"PJ Declerck","year":"1995","unstructured":"Declerck PJ, Verstreken M, Collen D: Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 74: 1305-1309, 1995","journal-title":"Thromb Haemost"},{"key":"357942_CR22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.2910580622","volume":"58","author":"H Solberg","year":"1994","unstructured":"Solberg H, R\u00f8mer J, Br\u00fcnner N, Holm A, Sidenius N, Dan\u00f8 K, H\u00f8yer-Hansen G: A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 58: 877-881, 1994","journal-title":"Int J Cancer"},{"key":"357942_CR23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/0959-8049(96)00118-9","volume":"32A","author":"TJ Benraad","year":"1996","unstructured":"Benraad TJ, Geurts-Moespot J, Gr\u00f8ndahl-Hansen J, Schmitt M, Heuvel JJTM, de Witte JH, Foekens JA, Leake RE, Br\u00fcnner N, Sweep CGJ: Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA)-report of an EORTC\/BIOMED-1 work-shop. Eur J Cancer 32A: 1371-1381, 1996","journal-title":"Eur J Cancer"},{"key":"357942_CR24","doi-asserted-by":"crossref","unstructured":"McCullagh P, Nelder JA: Generalized Linear Models. In: Chapman, Hall (eds), New York, 1989, pp 152-152","DOI":"10.1007\/978-1-4899-3242-6"},{"key":"357942_CR25","unstructured":"Diggle PJ, Liang K, Zeger SL: Analysis of Longitudinal Data. Clarendon Press, 1994, pp 201-202"},{"key":"357942_CR26","first-page":"174","volume":"107","author":"PD Brown","year":"1999","unstructured":"Brown PD: Clinical studies with matrix metalloproteinase inhibitors. Acta Pathol Microbiol Scand A 107: 174-180, 1999","journal-title":"Acta Pathol Microbiol Scand A"},{"key":"357942_CR27","first-page":"2087","volume":"53","author":"B Davies","year":"1993","unstructured":"Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-2091, 1993","journal-title":"Cancer Res"},{"key":"357942_CR28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ijc.2910580326","volume":"58","author":"RG Chirivi","year":"1994","unstructured":"Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 460-464, 1994","journal-title":"Int J Cancer"},{"key":"357942_CR29","first-page":"2513","volume":"53","author":"J Gr\u00f8ndahl-Hansen","year":"1993","unstructured":"Gr\u00f8ndahl-Hansen J, Christensen IJ, Rosenquist C, Br\u00fcnner N, Mouridsen HT, Dan\u00f8 K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993","journal-title":"Cancer Res"},{"key":"357942_CR30","first-page":"4043","volume":"47","author":"AP Sappino","year":"1987","unstructured":"Sappino AP, Busso N, Belin D, Vassalli JD: Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 47: 4043-4046, 1987","journal-title":"Cancer Res"},{"key":"357942_CR31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-230X(08)60028-7","volume":"44","author":"K Dan\u00f8","year":"1985","unstructured":"Dan\u00f8 K, Andreasen PA, Gr\u00f8ndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985","journal-title":"Adv Cancer Res"},{"key":"357942_CR32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jcb.240530206","volume":"53","author":"J Jankun","year":"1993","unstructured":"Jankun J, Merrick HW, Goldblatt PJ: Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53: 135-144, 1993","journal-title":"J Cell Biochem"},{"key":"357942_CR33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/bjc.1995.419","volume":"72","author":"R Hildenbrand","year":"1995","unstructured":"Hildenbrand R, Dilger I, Horlin A, Stutte HJ: Urokinase and macrophages in tumour angiogenesis. Br J Cancer 72: 818-823, 1995","journal-title":"Br J Cancer"},{"key":"357942_CR34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0092-8674(90)90009-4","volume":"62","author":"R Montesano","year":"1990","unstructured":"Montesano R, Pepper MS, M\u00f6hle-Steinle in U, Risau W, Wagner EF, Orci L: Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62: 435-445, 1990","journal-title":"Cell"},{"key":"357942_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/molehr\/3.1.27","volume":"3","author":"DL Hulboy","year":"1997","unstructured":"Hulboy DL, Rudolph LA, Matrisian LM: Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 3: 27-45, 1997","journal-title":"Mol Hum Reprod"},{"key":"357942_CR36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00210790","volume":"14","author":"S. Wojtowicz-Praga","year":"1996","unstructured":"Wojtowicz-Praga S., Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ: Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14: 193-202, 1996","journal-title":"Invest New Drugs"},{"key":"357942_CR37","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1998.16.6.2150","volume":"16","author":"S Wojtowicz-Praga","year":"1998","unstructured":"Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ: Phase I trial ofMarimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16: 2150-2156, 1998","journal-title":"J Clin Oncol"},{"key":"357942_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1006061115909","volume":"50","author":"C Benaud","year":"1998","unstructured":"Benaud C, Dickson RB, Thompson EW: Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 50: 97-116, 1998","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1012217820507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1012217820507\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1012217820507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1012217820507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:33:55Z","timestamp":1750480435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1012217820507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["357942"],"URL":"https:\/\/doi.org\/10.1023\/a:1012217820507","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}